Skip to content
Screener

Boston Scientific BSX MedSurg — Research and development expenses

Similar metrics at other companies

Mineralys Therapeutics, Inc. logo
MLYSResearch and development expenses
$4.59M-52.5%
Roivant Sciences logo
ROIVResearch and development expenses
$113.44M+128%
Vir Biotechnology, Inc. logo
VIRResearch and development expenses
$35.47M-9.8%
Vir Biotechnology, Inc. logo
VIRResearch and development expenses
$35.47M-9.8%
Titan International logo
TWIConsumer — Research and development expenses
$1.01M+13.3%
Titan International logo
TWIAgriculture — Research and development expenses
$1.49M+9.7%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$69.19B-54.6%
P/E18.9×-42.3×
P/S3.3×-5.0×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept bsx:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostAdjusted.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions, except percentages)Med Surg% of Net SalesCardiovascular% of Net SalesTotal
Segment expenses:
Cost of products sold47828.1%1,06730.5%
Selling, general and administrative expenses55732.8%95927.4%
Research and development expenses1277.5%3439.8%
Other segment items(1)50.3%70.2%
Segment operating income(2)53331.3%1,12532.1%1,658
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(199)

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's medsurg — research and development expenses?
Boston Scientific (BSX) reported medsurg — research and development expenses of $127M in Q1 2026.
How has Boston Scientific's medsurg — research and development expenses changed year-over-year?
Boston Scientific's medsurg — research and development expenses increased by 5.0% year-over-year, from $121M to $127M.
What is the long-term trend for Boston Scientific's medsurg — research and development expenses?
Over 3 years (2022 to 2025), Boston Scientific's medsurg — research and development expenses has grown at a 5.5% compound annual growth rate (CAGR), from $432M to $507M.
What does medsurg — research and development expenses mean?
Costs incurred by the MedSurg segment for the research, development, and clinical testing of new medical devices and technologies. This represents the segment's commitment to innovation and future product pipelines.

Ask your AI about Boston Scientific's medsurg — research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude